Carcinogenesis — Chemical, Radiation, Viral

Chemical Carcinogenesis

Initiation Phase (DNA Damage)

• Chemical carcinogens undergo metabolic activation in hepatic cytochrome P450 systems (especially CYP1A2, CYP2E1) to form highly reactive electrophilic intermediates
• These ultimate carcinogens bind covalently to DNA bases (forming DNA adducts), predominantly at the N7 position of guanine, causing point mutations and chromosomal aberrations
• Mutations preferentially occur in proto-oncogenes (RAS, MYC, ERBB2) and tumor suppressors (TP53, RB, APC), shifting them toward malignant phenotype
• Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke and nitrosamines in processed meats exemplify this mechanism

Promotion Phase (Clonal Expansion)

• Initiated cells with growth-promoting mutations expand clonally under selective pressure
• Promoters (phorbol esters, estrogens, chronic inflammation) enhance proliferation without directly damaging DNA
• Repeated cycles of cell division increase probability of acquiring additional oncogenic mutations
• Dose-response relationship and threshold effects characterize chemical carcinogenesis, distinct from radiation's linear no-threshold model

Progression Phase (Malignant Conversion)

• Accumulation of additional mutations drives transition from benign hyperplasia → dysplasia → carcinoma in situ → invasive cancer
• Loss of contact inhibition, gain of immortality (telomerase reactivation), and acquisition of angiogenic capacity occur
• Inactivation of apoptotic surveillance (p53 mutations allow escape from DNA damage checkpoints) facilitates progression
• Genetic instability amplifies acquisition rate of subsequent mutations

Radiation Carcinogenesis

Ionizing Radiation (IR) Mechanisms

• Direct effects: Ionizing photons (gamma rays, X-rays) and particles (alpha, beta) deposit energy directly in DNA, causing double-strand breaks (DSBs) and single-strand breaks
• Indirect effects: Production of free radicals and reactive oxygen species (ROS) from water radiolysis, causing oxidative DNA damage
• Non-homologous end joining (NHEJ) repair of DSBs is error-prone, generating point mutations and chromosomal aberrations (translocations, deletions)
• Linear no-threshold (LNT) model: Risk is proportional to dose with no safe threshold; even low-dose exposure carries malignant potential
• Latency period typically 10-20+ years (longer for solid tumors; shorter for leukemia ~5-7 years)
• Dose-rate effects: Protracted low-dose-rate exposure allows more efficient DNA repair, reducing carcinogenic risk compared to acute high-dose exposure

Non-ionizing Radiation (UV Light)

• Ultraviolet A (UVA) and ultraviolet B (UVB) cause thymine dimers and other photoproducts in DNA
• Defective nucleotide excision repair (NER) (as in xeroderma pigmentosum) profoundly increases skin cancer risk
• UV directly mutates TP53 ("sunburn" mutations) and activates MAPK and PI3K pathways, driving melanoma and nonmelanoma skin cancers

Viral Carcinogenesis

Direct Transformation Mechanisms

• Oncogenic retroviruses (HTLV-1) carry viral oncogenes (v-onc) that directly transform cells through constitutive signaling
• DNA viruses (HPV, EBV, HBV, HCV) encode viral oncoproteins that inactivate tumor suppressors:
• HPV E6 protein binds p53 and targets it for degradation; HPV E7 protein inactivates Rb, eliminating G1/S checkpoint control
• EBV LMP1 mimics CD40 signaling, promoting B-cell proliferation and survival
• HBV X protein disrupts p53 and transactivates oncogenic pathways
• Insertional mutagenesis: Viral DNA integration into genome disrupts normal genes or activates proto-oncogenes by providing strong promoter elements

Indirect Mechanisms

• Chronic inflammation from persistent viral infection (HBV, HCV, HPV) creates tumor microenvironment with elevated cytokines (IL-6, TNF-α), growth factors, and ROS
• Chronic inflammation drives oxidative stress-induced mutations and genomic instability through impaired DNA repair
• Viral-induced cellular proliferation increases replication-dependent mutation rate
• Immune evasion: Viruses suppress antiviral immunity, preventing clearance of transformed cells

Chemical Carcinogens

Occupational and Environmental Exposure

• Tobacco smoke: PAHs, nitrosamines, and aromatic amines cause lung, oral, esophageal, bladder, and pancreatic cancers; contains >70 known carcinogens
• Asbestos: Amphibole fibers (crocidolite, amosite) cause mesothelioma and lung cancer through chronic inflammation and ROS generation; latency 20-50 years
• Aflatoxin B1: Fungal mycotoxin contaminating grains; CYP3A4 metabolizes to aflatoxin B1-8,9-epoxide, a potent hepatocarcinogen; major risk factor for hepatocellular carcinoma in Africa and Asia
• Aromatic amines: Aniline, 2-naphthylamine, benzidine in rubber and dye manufacturing cause bladder cancer
• Vinyl chloride: Plastics manufacturing; causes angiosarcoma of liver through formation of chloroethylene oxide
• Benzene: Solvent exposure causes acute myeloid leukemia through bone marrow suppression and direct leukemogenic transformation

Dietary and Lifestyle

• Processed and red meat: Heterocyclic amines (HCAs) and N-nitroso compounds from cooking and curing increase colorectal cancer risk
• Alcohol: Ethanol and acetaldehyde metabolites cause oral, esophageal, liver, and breast cancers through inflammation and ROS; synergistic with tobacco
• Estrogen/Hormone replacement therapy: Prolonged use increases breast and endometrial cancer risk through persistent proliferative signaling

Radiation Carcinogenesis

Ionizing Radiation Exposure

• Atomic bomb radiation (Hiroshima/Nagasaki): Dose-dependent increased risk for leukemia (peak at 5-10 years), solid tumors (peak at 10-50 years)
• Medical radiation: Diagnostic X-rays (cumulative dose), CT imaging, nuclear medicine; medical staff occupational exposure
• Nuclear accidents: Chernobyl and Fukushima demonstrated increased thyroid cancer (iodine-131 uptake) and leukemia risk
• Occupational exposure: Uranium/radium miners, radiologists, nuclear industry workers; cumulative dose-dependent risk
• Radon: Naturally occurring radioactive gas; second leading cause of lung cancer after tobacco smoke, especially in underground miners

Non-ionizing Radiation

• Ultraviolet radiation (solar UV): Ambient sun exposure and artificial tanning beds; chief carcinogen for melanoma, basal cell carcinoma, and squamous cell carcinoma
• Latitude effect: Higher UV intensity in equatorial regions correlates with increased skin cancer incidence

Viral Oncogenic Agents

DNA Viruses

• Human papillomavirus (HPV): Persistent high-risk types (16, 18, 31, 33, 45) cause cervical, anal, oropharyngeal, penile, and vulvar cancers through E6/E7-mediated p53/Rb inactivation
• Hepatitis B virus (HBV): Chronic infection → cirrhosis → hepatocellular carcinoma; integration of HBV DNA and HBx-mediated carcinogenesis
• Hepatitis C virus (HCV): RNA virus; chronic inflammation and oxidative stress drive hepatocellular carcinoma without typical integration mechanism
• Epstein-Barr virus (EBV): Associated with Burkitt lymphoma (8;14 translocation), nasopharyngeal carcinoma (especially in Southeast Asia), post-transplant lymphoproliferative disorder (PTLD)
• Human herpesvirus 8 (HHV-8): Causes Kaposi sarcoma in immunocompromised hosts (AIDS, transplant recipients) through viral IL-6 and LANA-mediated transformation
• Merkel cell polyomavirus: Associated with Merkel cell carcinoma

Retroviruses

• Human T-cell leukemia virus-1 (HTLV-1): Causes adult T-cell leukemia/lymphoma (ATLL) through Tax-mediated NF-κB and MAPK signaling; endemic in southern Japan, Caribbean
• Human immunodeficiency virus (HIV): Not directly transforming but enables opportunistic viruses (HHV-8, EBV, HPV) and impairs immune surveillance of transformed cells

Chemical Carcinogenesis

Tobacco-Related Cancers

• Lung cancer: Progressive dyspnea, chronic cough (may be productive with hemoptysis), chest pain, hoarseness from recurrent laryngeal nerve involvement
• Oral and esophageal cancers: Dysphagia, odynophagia, oral ulcers or masses, hoarseness
• Bladder cancer: Painless gross hematuria (cardinal symptom), dysuria, increased frequency
• Physical exam: Cachexia, lymphadenopathy (metastatic disease)

Asbestos-Related Malignancy

• Mesothelioma: Progressive dyspnea, chest wall pain, cough; pleural effusion on examination with restrictive pattern on pulmonary function tests
• Latent period often 20-50 years post-exposure; occupational history essential
• Imaging: Pleural thickening, nodules, eventual massive pleural effusion

Aflatoxin B1 Hepatocarcinogenesis

• Chronic liver disease symptoms: Abdominal pain, jaundice, ascites, spider angiomata
• Advanced cirrhosis with portal hypertension
• Rapid clinical deterioration in setting of chronic HBV and aflatoxin co-exposure

Radiation-Induced Malignancy

Acute Radiation Syndrome (High-dose exposure)

• Prodromal phase: Nausea, vomiting, diarrhea within hours
• Latent phase: Apparent recovery
• Manifest illness: Hemorrhage, infection, diarrhea, electrolyte derangement

Delayed Carcinogenesis (Lower doses)

• Leukemia: Fatigue, petechiae, ecchymosis, infections from marrow failure (typically 5-10 years post-exposure)
• Solid tumors: Organ-specific manifestations depending on site (thyroid nodule from thyroid cancer, lung masses, etc.); peak incidence 10-50 years post-exposure
• Cataracts: Lens opacification; non-malignant but dose-dependent late effect

UV-Induced Skin Cancer

• Melanoma: Asymmetric pigmented lesion with irregular borders, color variegation (ABCDE: Asymmetry, Border irregularity, Color, Diameter >6mm, Evolving/Elevation)
• Nonmelanoma (basal cell, squamous cell): Painless nodule or ulcer on sun-exposed skin; slow growth typically

Viral Oncogenesis

HPV-Related Malignancies

• Cervical cancer: Abnormal vaginal bleeding/discharge, pelvic pain (advanced disease), dyspareunia
• Oropharyngeal cancer: Throat pain, dysphagia, neck mass (cervical lymphadenopathy)
• Physical exam: Cervical ulcer, tonsillar exudate or mass

HBV/HCV-Related Hepatocellular Carcinoma

• Insidious presentation in cirrhotic liver: Abdominal pain, weight loss, hepatomegaly with nodular surface
• Signs of decompensation: Ascites, jaundice, variceal bleeding, encephalopathy
• Paraneoplastic syndromes: Hypoglycemia, erythrocytosis

EBV-Associated Malignancies

• Burkitt lymphoma: Rapidly enlarging abdominal mass, constitutional symptoms (fever, night sweats, weight loss), gastrointestinal obstruction
• Nasopharyngeal carcinoma: Unilateral nasal obstruction, epistaxis, cervical lymphadenopathy, otitis media from Eustachian tube obstruction

HHV-8-Associated Kaposi Sarcoma

• AIDS patients: Violaceous macules and papules on skin and oral mucosa; may precede systemic involvement
• Lymphedema of affected extremities; visceral involvement (GI, pulmonary) in advanced disease
• Physical exam: Multiple purple/red nodules, blanching with pressure

Histological Findings

Chemical Carcinogenesis Morphology

• Dysplasia (graded low-grade vs. high-grade): Increased nuclear size (↑N:C ratio), hyperchromasia, coarse chromatin, irregular nuclear membranes, increased mitotic rate including abnormal forms
• Carcinoma in situ: Full-thickness epithelial involvement without stromal invasion; intact basement membrane
• Invasive carcinoma: Nests/cords of malignant cells breaching basement membrane into underlying stroma with desmoplastic stromal response (fibrous tissue reaction)
• Specific histotypes depend on organ: squamous cell carcinoma (lung, esophagus, bladder), adenocarcinoma (lung, colon)

Asbestos-Related Mesothelioma

• Biphasic pattern: Mix of epithelioid and sarcomatoid (spindle cell) components
• Long slender fibers in lung tissue (asbestos bodies with iron-protein coating visible on Prussian blue stain)
• Cuboidal epithelial cells lining slit-like spaces; invasion of underlying adipose tissue
• Immunohistochemical profile: Positive for mesothelial markers (calretinin, WT1, D2-40); negative for adenocarcinoma markers (MOC-31, B72.3)

Radiation-Induced Malignancy Histology

• Acute leukemia (post-radiation): High cellularity bone marrow with immature blasts, diminished normal hematopoiesis
• Solid tumors: Morphology determined by tissue of origin; may have elevated mitotic index and cytologic atypia
• Thyroid cancer (post-radioiodine): Typically papillary thyroid carcinoma with characteristic nuclear grooves and pseudoinclusions

UV-Induced Skin Cancer Histology

• Melanoma: Cytologic atypia in melanocytes (enlarged nuclei, prominent nucleoli), increased mitotic rate, asymmetric distribution, ulceration, infiltration into dermis/subcutis; Clark level and Breslow thickness determine stage
• Basal cell carcinoma: Basaloid nests with peripheral palisading, retraction artifact around nests, apoptotic bodies
• Squamous cell carcinoma: Infiltrating nests of keratinizing squamous epithelium with horn pearls

Immediate stabilisation (acute exposure events)

• Radiation incident triage: remove clothing and decontaminate (external), then obtain serial absolute lymphocyte counts — the rate of lymphocyte depletion estimates dose. Per CDC/HHS Radiation Emergency Medical Management guidance, hematopoietic subsyndrome is treated with myeloid growth factors (filgrastim), transfusion support with irradiated/leukoreduced products, and antimicrobials for neutropenic fever.
• Internal contamination antidotes (isotope-specific): potassium iodide blocks thyroid uptake of radioiodine (greatest benefit in children/pregnancy, minimal in older adults per FDA guidance); Prussian blue for cesium-137/thallium; DTPA for plutonium/americium.

First-line: primary prevention (the actual "drug therapy" of carcinogenesis)

• Tobacco cessation pharmacotherapy: partial nicotinic agonist (varenicline) is favored first-line, with nicotine replacement and bupropion as alternatives (USPSTF recommends behavioral plus pharmacologic therapy for all adults who smoke).
• Vaccination: HPV 9-valent vaccine routinely at age 11–12, catch-up through 26, shared decision-making 27–45 (CDC/ACIP); universal HBV vaccination of infants and all unvaccinated adults through age 59 (ACIP).
• Exposure control: OSHA/NIOSH engineering controls for asbestos, benzene, aromatic amines, vinyl chloride; EPA radon mitigation; broad-spectrum sunscreen and photoprotection (USPSTF counseling recommendation for fair-skinned individuals).

Escalation — antiviral suppression and surveillance

• Chronic HBV: nucleos(t)ide analogue (entecavir or tenofovir) suppresses viral replication and lowers HCC incidence (AASLD).
• Chronic HCV: direct-acting antivirals (sofosbuvir/velpatasvir) for essentially all infected patients (AASLD/IDSA HCV Guidance); HIV control with antiretroviral therapy causes regression of many Kaposi sarcoma lesions.
• Surveillance: low-dose CT annually, ages 50–80 with ≥20 pack-years currently smoking or quit within 15 years (USPSTF); cervical cytology/hrHPV testing per USPSTF and ASCCP risk-based management; abdominal ultrasound ± AFP every 6 months in cirrhosis (AASLD).

Definitive management

• Surgical resection of the resulting neoplasm with stage-directed chemotherapy, radiotherapy, or immunotherapy per NCCN disease-specific guidelines; excision with margin control (Mohs for selected facial nonmelanoma skin cancer, wide local excision by Breslow depth for melanoma).

Contraindicated

• Beta-carotene supplementation in smokers/asbestos-exposed — increased lung cancer incidence in the ATBC and CARET trials.
• Continued antiviral-free observation of viremic HBV cirrhosis, and abandoning HCC surveillance after DAA cure in cirrhotics (risk falls but persists).

Complications of the malignant process

• Tumor lysis syndrome — emergency: massive turnover in rapidly proliferating EBV-driven Burkitt lymphoma releases intracellular contents; hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia with acute kidney injury. Signaled by rising potassium and creatinine after therapy initiation; rasburicase and aggressive hydration are used.
• Malignant hypercalcemia — emergency: HTLV-1 adult T-cell leukemia/lymphoma secretes PTHrP and osteoclast-activating cytokines; presents with confusion, polyuria, short QT.
• Ureteral obstruction/uremia in advanced HPV-associated cervical carcinoma from parametrial invasion — hydronephrosis on imaging; the classic cause of death.
• Variceal hemorrhage, decompensation, and tumor rupture with hemoperitoneum in HBV/HCV/aflatoxin-related hepatocellular carcinoma — emergency; abrupt abdominal pain with hemodynamic collapse.
• Trapped lung and recurrent malignant pleural effusion in mesothelioma from encasing pleural rind; progressive dyspnea despite drainage.
• Superior vena cava syndrome and malignant spinal cord compression — emergencies; facial plethora with distended neck veins, or back pain with a sensory level. Urgent MRI plus corticosteroids for cord compression.

Complications of treatment (iatrogenic carcinogenesis is itself testable)

• Alkylating agents (cyclophosphamide, melphalan): therapy-related MDS/AML after roughly 5–7 years, with chromosome 5 and 7 deletions; preceded by cytopenias.
• Topoisomerase II inhibitors (etoposide): therapy-related AML within 1–3 years, KMT2A/MLL 11q23 translocation, often monocytic.
• Cyclophosphamide acrolein metabolite: hemorrhagic cystitis and later urothelial carcinoma — hematuria; mesna is protective.
• Tamoxifen: partial estrogen agonism in endometrium → endometrial carcinoma; postmenopausal bleeding is the signal.
• Therapeutic radiation: pneumonitis and fibrosis, constrictive pericarditis, esophageal stricture, hypothyroidism, and second solid cancers/sarcomas (including angiosarcoma in an irradiated field) after long latency.
• Anthracyclines: dose-dependent cardiomyopathy from iron-mediated free radicals; falling ejection fraction on surveillance echocardiography.

• **Aflatoxin B1 → TP53 codon 249 G:C→T:A transversion**: the single most testable carcinogen–mutation pair. Stem cues: stored grain/peanuts, sub-Saharan Africa or East Asia, co-infection with HBV (synergistic, not merely additive).
• Match the agent to the tumor: vinyl chloride and arsenic → hepatic angiosarcoma; 2-naphthylamine/benzidine (dye, rubber, leather) → urothelial carcinoma; benzene → AML; asbestos → lung cancer more often than mesothelioma, and asbestos plus smoking is multiplicative for lung cancer but not for mesothelioma.
• Best next step for painless gross hematuria in an older adult or dye/rubber worker: cystoscopy with upper-tract imaging (CT urography), not urine cytology alone and not a repeat urinalysis.
• Viral oncoprotein targets: HPV E6 degrades p53, E7 inactivates Rb — remember E6/E7 in numerical order matching p53 then Rb. Koilocytes (perinuclear halo, raisinoid nucleus) are the histologic buzzword.
• EBV buzzwords: starry-sky pattern with t(8;14) *MYC*–IgH in Burkitt lymphoma; nasopharyngeal carcinoma in Southeast Asian adults; PTLD in a transplant recipient on calcineurin inhibitors — first step is reduction of immunosuppression.
• HTLV-1 ATLL: flower cells (multilobated lymphocytes), lytic bone lesions, and hypercalcemia in a patient from Japan or the Caribbean.
• Radiation latency splits the answer: leukemia peaks around 5–10 years; solid tumors (thyroid, breast, lung) take a decade or more. Childhood radioiodine exposure → papillary thyroid carcinoma with nuclear grooves and Orphan Annie eye nuclei.
• Common distractors: HCV is an RNA virus that does not integrate — it drives cancer through chronic inflammation and cirrhosis, unlike HBV; HPV vaccination does not replace cervical screening; alpha-1 antitrypsin/smoking questions are lung-distribution traps, not carcinogenesis; and H. pylori (gastric adenocarcinoma, MALT lymphoma) is bacterial, not viral.